Following Vounatsos' announced departure, Biogen partners with private Canadian biotech for oral Parkinson's treatment

Lei Lei Wu

News Reporter

Biogen announced a deal with Canadian biotech Alectos Therapeutics on Monday to develop a drug aimed at restoring lysosome function, adding another candidate to the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Following Vounatsos' announced departure, Biogen partners with private Canadian biotech for oral Parkinson's treatment

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Fol­low­ing Vounatsos' an­nounced de­par­ture, Bio­gen part­ners with pri­vate Cana­di­an biotech for oral Parkin­son's treat­ment

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Following Vounatsos' announced departure, Biogen partners with private Canadian biotech for oral Parkinson's treatment